Erasca

Erasca is built on the thesis that the RAS/MAPK signaling pathway is the single most important oncogenic driver across human cancers, implicated in roughly 30% of all tumors. Rather than targeting one node in isolation, the company pursues multiple points along the pathway — upstream, midstream, and downstream — with small molecules, biologics, and computational discovery tools. The name 'Erasca' is a deliberate contraction of 'erase cancer.'

Jonathan E. Lim founded Erasca in 2018 after serving as CEO of Ignyta, a precision oncology company he led from founding through its acquisition by Roche. Roche paid $1.7 billion for Ignyta in early 2018, acquiring its lead asset entrectinib, a targeted therapy for NTRK- and ROS1-positive solid tumors. Lim co-founded Ignyta in 2011 and grew it into a publicly traded company before the sale.

Erasca uses a hybrid model that combines internal discovery with in-licensing and acquisitions of clinical-stage assets. ERAS-007 was in-licensed from Ascentage Pharma, and the KRAS G12C inhibitor program later named ERAS-3490 was acquired from Novartis in early 2022. The internal discovery work centers on Erasca's three proprietary platforms targeting different modalities of RAS-pathway inhibition.

ERAS-007 is an oral ERK1/2 inhibitor being evaluated in combination with EGFR inhibitors, SHP2 inhibitors, and KRAS G12C inhibitors in non-small cell lung cancer and colorectal cancer. ERAS-801 is a brain-penetrant EGFR inhibitor in development for glioblastoma. A December 2023 collaboration with Eli Lilly pairs ERAS-007 with Lilly's KRAS G12C inhibitor in a Phase 1b/2 clinical trial.

Erasca is a publicly traded biotech company that operates with the capital-aggregation discipline of a venture platform. The company raised an unusually large $200 million Series B in early 2021 and immediately filed for an IPO, raising another $300 million within the same year. This 'super-round then IPO' sequencing, combined with Lim's track record of acquiring undervalued assets from larger pharma, gives the firm a capital-deployment posture closer to a biotech holding company than a single-asset biotech.

In December 2022, Erasca announced a restructuring that reduced its workforce by approximately 40%, eliminating roles across research and early development to extend its cash runway into 2026. The company stated the move was designed to prioritize capital allocation toward its most advanced clinical-stage programs, particularly ERAS-007 and ERAS-801, while pausing earlier-stage discovery work.

The IPO registration and early funding documentation name ARCH Venture Partners, Cormorant Asset Management, and City Hill Ventures as early significant investors. The firm attracted a syndicate of blue-chip biotech crossover funds typical of late-stage private rounds that bridge into public offerings.